PLAY PODCASTS
Audio Journal of Oncology Podcast

Audio Journal of Oncology Podcast

Leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals

Audio Medica News

211 episodesEN-GB

Show overview

Audio Journal of Oncology Podcast has been publishing since 2018, and across the 8 years since has built a catalogue of 211 episodes. That works out to roughly 30 hours of audio in total. Releases follow a monthly cadence.

Episodes typically run under ten minutes — most land between 7 min and 11 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-GB-language Science show.

The show is actively publishing — the most recent episode landed 1 weeks ago, with 105 episodes already out so far this year. The busiest year was 2026, with 105 episodes published. Published by Audio Medica News.

Episodes
211
Running
2018–2026 · 8y
Median length
9 min
Cadence
Monthly

From the publisher

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

Latest Episodes

View all 211 episodes

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

Sep 8, 20268 min

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

Aug 31, 202612 min

David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer

Aug 25, 20263 min

Robert C. Stein, PhD FRCP; ASCO 2026: Gene Test Finds Most Patients with High Risk ER-positive, HER2-negative Early Breast Cancer Do Not Benefit from Chemotherapy

Aug 17, 202611 min

Bjørn Henning Grønberg MD PhD; ASCO 2026: Adding Thoracic Radiotherapy Did Not Prolong Lives of Patients with Extensive Stage Small Cell Lung Cancer Being Treated with Chemo-Immunotherapy. COMMENT: David R Spigel MD

Jul 22, 20269 min

Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies

Jul 14, 20267 min

Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations

Jul 8, 20269 min

Ghassan K. Abou-Alfa MD PhD; ASCO 2026: Adding Doublet Immune Checkpoint Inhibition to Embolization with or without anti-Growth Factor TKI Therapy Extends Progression Free Survival in Patients with Hepatocellular Cancer

Jun 30, 20268 min

Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results

Jun 23, 20269 min

Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma

Jun 15, 20267 min

Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma

Jun 15, 20267 min

Jana de Boniface MD PhD; ASCO 2026: Omitting Axillary Lymph Node Dissection is Safe for Patients with Breast Cancer Macrometastases to One or Two Sentinel Lymph Nodes

Jun 11, 20266 min

Jana de Boniface MD PhD; ASCO 2026: Omitting Axillary Lymph Node Dissection is Safe for Patients with Breast Cancer Macrometastases to One or Two Sentinel Lymph Nodes

Jun 11, 20266 min

Jean-Marc Classe, MD PhD; ASCO 2026: Timing of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles: Early Findings from Randomized CHRONO Trial

Jun 9, 20269 min

Jean-Marc Classe, MD PhD; ASCO 2026: Timing of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles: Early Findings from Randomized CHRONO Trial

Jun 9, 20269 min

Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer

Jun 5, 20268 min

Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer

Jun 5, 20268 min

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Jun 4, 202610 min

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Jun 4, 202610 min

Eileen M O’Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

Jun 2, 202613 min